Company Overview
- Headquarters
- 142 Sansome St Fl 2, San Francisco CA
- Website
- 89bio.com
- Phone
- (415) 432-9270
- Employees
- 121
- Founded in
- 2018
- Industry
- BioTech/Drugs
- NAICS Code
-
NAICS Code 541 CompaniesNAICS Code 32 CompaniesNAICS Code 325 CompaniesNAICS Code 54 CompaniesNAICS Code 3254 CompaniesNAICS Code 32541 Companies
- SIC Code
-
SIC Code 283 CompaniesSIC Code 28 CompaniesSIC Code 873 CompaniesSIC Code 87 Companies
Financials & Stats
Revenue
$9B
Who is 89Bio
89bio is a clinical-stage biopharmaceutical company headquartered in San Francisco, California. The company employs 121 people and has generated $8.7 million in revenue. 89bio focuses on developing and commercializing innovative therapies for liver and cardio-metabolic diseases. Their lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21, designed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Recent clinical trials have shown BIO89-100 to be safe and well-tolerated, with promising results in reducing liver fat and key lipid markers in patients with NASH. The company is currently conducting a Phase 2 trial for BIO89-100 in the treatment of SHTG. For more information about 89bio and their therapeutic pipeline, visit their website at 89bio.com.
Company Leadership
89Bio Tech Stack
Companies Similar to 89Bio
Analyze industry trends and opportunities by examining competitors and companies comparable to 89Bio, including their performance metrics, financials, growth dynamics, and competitive benchmarks.
| Company Name | Revenue | Number of Employees | Location | Founded in |
|---|---|---|---|---|
| 9M | 63 | Ames, IA | 2015 | |
| 9M | 113 | Seattle, WA | 2014 | |
| 9M | 5 | Savage, MD | 2000 | |
| 9M | 6 | Parsippany, NJ | 2012 | |
| 9M | 1 | Cambridge, MA | 2009 |